Physician profile
John Andrew Johnson
NPI 1043650641
$29,632.68
in general payments reported to CMS, 2019-2025
38 companies · $2,480 in 2025
The $2,480 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,596 · 2020: $11K · 2021: $6,911 · 2022: $1,747 · 2023: $1,584 · 2024: $2,502 · 2025: $2,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,446 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,446.21 |
| Education | $120.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,496.31 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $9,166.01 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,383.35 | 2019-2025 | Dupixent |
| Genzyme Corporation | $937.28 | 2019-2025 | |
| Csl Behring | $594.21 | 2019-2025 | Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $574.47 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Novartis Pharmaceuticals Corporation | $565.13 | 2019-2025 | |
| Grifols USA, LLC | $409.20 | 2019-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Amgen INC. | $393.50 | 2022-2024 | Tezspire |
| Genentech USA, INC. | $384.46 | 2020-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.40 | 2019-2023 | Spiriva Respimat |
| Alk-Abello, INC | $261.47 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $253.67 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $207.89 | 2019-2025 | Ruconest |
| Pfizer INC. | $196.75 | 2020-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $182.45 | 2022-2024 | Adbry |
| Kaleo, INC. | $178.67 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $128.65 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $118.81 | 2025 | Neffy |
| Shire North American Group INC | $110.42 | 2019 | |
| Mylan Specialty L.P. | $102.59 | 2021-2023 | Yupelri |
| Aimmune Therapeutics, INC. | $96.71 | 2020-2023 | |
| Optinose US, INC. | $88.41 | 2019-2025 | |
| Abbvie INC. | $80.03 | 2022-2025 | |
| Octapharma USA, INC. | $68.89 | 2021 | |
| Uswm, LLC | $43.00 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $40.09 | 2020 | |
| Ionis Pharmaceuticals, INC. | $38.21 | 2025 | Dawnzera |
| Organon LLC | $32.85 | 2025 | Vtama |
| X4 Pharmaceuticals, INC. | $32.03 | 2024 | Xolremdi |
| Invivyd INC | $31.06 | 2025 | Pemgarda |
| Verona Pharma, INC. | $23.07 | 2025 | Ohtuvayre |
| Gc Biopharma USA, INC. | $21.42 | 2025 | Alyglo |
| Galderma Laboratories, L.P. | $19.01 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $18.88 | 2021 | |
| Pulmonx Corporation | $16.55 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Viiv Healthcare Company | $15.75 | 2019 | |
| Cycle Pharmaceuticals INC | $8.03 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.